ArticleMolecular therapy : the journal of the American Society of Gene Therapy2016
Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Trial
- Advances in viral vector-based delivery systems for gene therapy: a comprehensive review.3 Biotech · 2025Review
- Monitoring for liver cancer post-gene therapy-How much and how often?Journal of viral hepatitis · 2024Review
- Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B.Blood advances · 2023Article
- Gene therapy for liver diseases - progress and challenges.Nature reviews. Gastroenterology & hepatology · 2023Review
- Cryo-electron Microscopy of Adeno-associated Virus.Chemical reviews · 2022Review
- Gene therapy in haemophilia: literature review and regional perspectives for Turkey.Therapeutic advances in hematology · 2022Review
- Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia.Journal of clinical medicine · 2021Review
- Genomics of Viral Hepatitis-Associated Liver Tumors.Journal of clinical medicine · 2021Review
- Large-scale molecular epidemiological analysis of AAV in a cancer patient population.Oncogene · 2021Article
- Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector.Molecular therapy. Methods & clinical development · 2021Article
- Hemophilia Gene Therapy: Approaching the First Licensed Product.HemaSphere · 2021Review
- Article
- Krabbe Disease: Prospects of Finding a Cure Using AAV Gene Therapy.Frontiers in medicine · 2021Review
- Review
- Intramuscular Delivery of Gene Therapy for Targeting the Nervous System.Frontiers in molecular neuroscience · 2020Article
- Update on clinical gene therapy for hemophilia.Blood · 2019Review
- Hepatocellular Adenoma in a Patient with Ornithine Transcarbamylase Deficiency.Case reports in hepatology · 2019Article
- Emerging Issues in AAV-MediatedMolecular therapy. Methods & clinical development · 2018Review
- Identification of liver-specific enhancer-promoter activity in the 3' untranslated region of the wild-type AAV2 genome.Nature genetics · 2017Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
19 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.